All About Multiple Sclerosis

More MS news articles for June 2003

Bone mineral density in patients with multiple sclerosis: the effects of interferon

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12766859&dopt=Abstract

Rev Neurol 2003 May 16-31;36(10):901-3
Perez Castrillon JL, Cano Del Pozo M, Sanz Izquierdo S, Velayos Jimenez J, Dib Wobakin W.
Hospital Rio Hortega, Valladolid, Espa a.

INTRODUCTION:

Patients with multiple sclerosis (MS) are at greater risk of suffering from osteoporosis and pathological fractures, and the use of corticoids together with immobilisation and vitamin D deficiency is one of the causes of low bone mass (BM).

AIMS:

Our aim was to evaluate the effect of interferon, a drug that has only recently been introduced in the treatment of the disease, on bone mineral density (BMD) and bone remodelling markers.

PATIENTS AND METHODS:

A total of 30 females and 18 males with MS were studied.

A standardised case history report was examined, and determinations of ionic calcium, vitamin D, osteocalcin, iPTH and urinary deoxypyridinoline, together with calcaneus densimetry measurements using a DEXA densimeter were also performed.

RESULTS:

The females treated with interferon had a BMD similar to that of those who had only received corticoids.

Yet the males treated with interferon had a BMD that was lower than that of those who had not been treated with this drug (0.484 0.104 g/cm2 compared to 0.631 0.143 g/cm2, p= 0.032) and the control group (0.484 0.104 g/cm2 compared to 0.581 0.102 g/cm2, p= 0.015).

No differences were found in the bone remodelling parameters.

CONCLUSIONS:

Males treated with interferon present a decrease in BM, and results are paradoxical because interferon plays a part in regulating bone metabolism and inhibits the development of osteoclasts, the cells responsible for bone resorption.